33333
4444

ENABLING EARLY AND LATE STAGE DRUG DEVELOPMENT FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

Theralink Technologies’ biopharma services will help benefit drug companies accelerate their drug discovery programs. Theralink’s technologies can be used to:

  • Stratify patients entering clinical trials (reduces trial costs up to 50% with smaller cohorts);
  • Monitor on and off target drug effects;
  • Quantify the phosphoproteome within tumors to identify activation of resistance or compensatory pathways post-treatment;
  • Evaluate potential proteomic biomarkers for combination therapies; and
  • Potentially repurpose existing therapies for new indications (off-patent drugs and market expansion).

SERVICES INCLUDE:

Laser Capture Microdissection (LCM) Services:

  • Procurement of pure cell populations (e.g. tumor cells only, stromal cells) from heterogenous tissue via laser-capture microdissection.
  • LCM for client's own process (i.e. perform LCM and send the microdissected cells back to the client for their in-house analysis).

Reverse Phase Protein Micro-Array (RPPA) Services:

  • Quantitative multi-target proteomic and phosphoproteomic profiling of human and animal tissues.
  • Quantitative multi-target proteomic and phosphoproteomic profiling of PDX (patient-derived xenograft) models.
  • Quantitative multi-target proteomic and phosphoproteomic profiling of cell lines.

Other Services:

  • Immunohistochemistry of FFPE and fresh-frozen tissues.
  • Cell culture of primary cells and/or immortalized cell lines.
  • Western blot antibody validation.
  • Tissue fixation for phosphoproteomic profiling, including molecular profiling of bony tissue.

SCIENCE BACKED BY STRONG LEADERSHIP

Meet the team that is the driving force behind our success.

View Management Team »